List of Excipients in Branded Drug ANORO ELLIPTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	ANORO ELLIPTA	umeclidinium bromide and vilanterol trifenatate	0173-0869	LACTOSE MONOHYDRATE	2030-11-29
GlaxoSmithKline LLC	ANORO ELLIPTA	umeclidinium bromide and vilanterol trifenatate	0173-0869	MAGNESIUM STEARATE	2030-11-29

Anoro Ellipta Excipient Strategy, Patent Protection, and Commercial Opportunities

Last updated: August 2, 2026

Anoro Ellipta is a dry-powder inhaler containing umeclidinium bromide and vilanterol trifenatate for once-daily maintenance treatment of chronic obstructive pulmonary disease. Its excipient strategy is deliberately narrow: lactose monohydrate acts as the carrier, magnesium stearate modifies powder performance, and the Ellipta device controls metering and delivery. The commercial opportunity is concentrated in inhalation-grade lactose, carrier engineering, device-compatible formulation development, generic dry-powder inhalers, and differentiated COPD products rather than in novel excipient composition alone. [1]

What is Anoro Ellipta and how is it formulated?

Anoro Ellipta combines a long-acting muscarinic antagonist, umeclidinium, with a long-acting beta2-adrenergic agonist, vilanterol.

Product attribute	Anoro Ellipta
Active ingredients	Umeclidinium bromide and vilanterol trifenatate
Delivered dose	Umeclidinium 62.5 mcg and vilanterol 25 mcg per inhalation
Dosage form	Dry powder inhaler
Administration	One inhalation once daily
Device	Ellipta inhaler
Indication	Maintenance treatment of airflow obstruction in COPD
Primary U.S. sponsor	GlaxoSmithKline, now operating within GSK
U.S. approval	May 18, 2013
Key excipients	Lactose monohydrate and magnesium stearate
Important formulation issue	Lactose contains milk proteins and is unsuitable for patients with severe milk-protein allergy

The powder is packaged in two foil blister strips within the Ellipta inhaler. One strip contains umeclidinium bromide and the other contains vilanterol trifenatate. Each blister is opened by the device as the dose is prepared for inhalation. [1]

The formulation does not use a liquid propellant, ethanol, surfactant, or capsule shell. This reduces the number of chemical excipients but shifts technical importance toward powder engineering, blister protection, dose metering, and airflow-driven dispersion.

What excipients are used in Anoro Ellipta?

Anoro Ellipta uses lactose monohydrate and magnesium stearate as the principal pharmaceutical excipients.

Lactose monohydrate

Lactose monohydrate is the bulking and carrier excipient. The active pharmaceutical ingredients are present at microgram quantities, so the carrier provides sufficient bulk for reproducible handling and delivery. Lactose also supports ordered-mixture formation, in which micronized active particles adhere to the surfaces of larger carrier particles before detaching during inhalation.

The commercial value of lactose depends on more than chemical identity. Relevant quality attributes include:

• Particle-size distribution
• Fine-particle fraction
• Surface roughness
• Moisture content
• Crystallinity
• Bulk density
• Flowability
• Microbial quality
• Lot-to-lot consistency

Lactose is widely used in dry-powder inhalers, which makes supply available from established pharmaceutical-grade producers. The constraint is the inhalation-grade specification, not basic lactose availability. Changes in particle morphology, fines content, or moisture can alter emitted dose and fine-particle mass without changing the nominal formulation.

The presence of milk proteins is a labeling and risk-management issue. The U.S. prescribing information states that Anoro Ellipta is contraindicated in patients with severe milk-protein hypersensitivity because lactose may contain milk proteins. [1]

Magnesium stearate

Magnesium stearate is used at a low level to improve powder behavior. In inhalation powders, it can reduce cohesion, modify surface energy, improve flow, and affect detachment of micronized drug from the carrier. It can also influence moisture sensitivity and the interaction between the powder and device surfaces.

Its effect is highly process-dependent. Variables include:

• Mixing intensity
• Order of addition
• Mixing time
• Magnesium stearate particle size
• Surface coverage of lactose
• Humidity during processing
• Storage conditions
• Device resistance and airflow

A formulation that uses magnesium stearate as a surface modifier may require tighter process controls than a simple blend. Over-coating can reduce active-carrier adhesion too much or alter aerosolization. Under-coating can produce poor flow and dose variability.

How does the Anoro Ellipta excipient strategy support product performance?

The excipient strategy supports four performance objectives: dose uniformity, powder flow, aerosol dispersion, and stability.

Dose uniformity

The active ingredients are delivered at low microgram doses. Uniform distribution through the carrier blend is therefore critical. The formulation must maintain content uniformity during filling, blister handling, storage, and device actuation.

Aerosol dispersion

The patient’s inhalation airflow disperses the powder. The device and formulation operate as a combined system. A formulation change that performs well in a laboratory inhaler may fail in Ellipta because of differences in airflow resistance, deagglomeration, or powder retention.

Moisture control

Moisture can increase powder cohesion, change lactose surface properties, and reduce dispersion. The foil blister and device packaging provide a moisture barrier. Packaging integrity is therefore part of the excipient strategy even though foil is not a pharmaceutical excipient.

Stability

Umeclidinium and vilanterol must remain chemically and physically stable throughout shelf life. The formulation must control degradation, powder aggregation, and changes in emitted dose. Stability work covers both active ingredients because the two drugs are stored in separate blister strips within the same inhaler.

What formulations are protected by Anoro Ellipta intellectual property?

Anoro Ellipta protection is likely distributed across several IP categories rather than confined to a single excipient patent.

IP category	Commercial relevance
Umeclidinium composition and use patents	Protect the LAMA active ingredient and COPD use
Vilanterol composition and use patents	Protect the LABA active ingredient and therapeutic use
Fixed-dose combination patents	Cover umeclidinium-vilanterol combinations and dosing
Dry-powder formulation patents	Cover carrier, surface modifier, particle properties, and blend ratios
Ellipta device patents	Cover blister handling, dose preparation, airflow, and inhaler architecture
Manufacturing patents	Cover blending, filling, strip assembly, sealing, and device loading
Method-of-use patents	May cover COPD maintenance dosing and treatment populations
Regulatory exclusivity	Delays certain generic approvals independently of patent term

The key strategic point is that a generic competitor may avoid one claim category and still face barriers in another. A formulation patent may be designed around different carrier ratios or surface treatments. A device patent may be avoided by using a different inhaler architecture. A combination patent may remain relevant even if the competitor develops a non-Ellipta device.

Patent scope must be assessed claim by claim. The presence of lactose and magnesium stearate in the approved product does not mean every lactose-based umeclidinium-vilanterol formulation infringes a formulation claim.

When does Anoro Ellipta lose exclusivity?

Anoro’s market exclusivity is governed by several separate dates:

1. New-drug exclusivity for the approved combination.
2. Patent protection for umeclidinium.
3. Patent protection for vilanterol.
4. Combination-product patents.
5. Formulation and device patents.
6. Approved method-of-use patents.
7. Pediatric exclusivity, if awarded to a relevant patent or exclusivity period.

Anoro was approved in 2013. Regulatory exclusivity does not equal complete market protection because patents may extend beyond regulatory exclusivity, while some patents may expire before the end of exclusivity.

The commercially relevant endpoint is the earliest legally viable generic entry date after considering:

• Listed patents in the Orange Book
• Patent expiration dates
• Patent-term adjustment
• Pediatric extensions
• Paragraph IV certifications
• Litigation-triggered stays
• Settlement terms
• Non-Orange-Book device or formulation patents
• FDA approval timing

The FDA Orange Book should be used for the current listed-patent record and exclusivity status. [2] Patent expiry calculations should use the specific patent, terminal disclaimer, patent-term adjustment, and any pediatric extension rather than a general estimate based on the 2013 approval date.

What is the Orange Book status of Anoro Ellipta?

Anoro Ellipta is an FDA-approved prescription combination drug and is evaluated through the drug-product pathway rather than the biosimilar pathway. Any U.S. generic applicant would generally need to address the reference listed drug through an abbreviated new drug application.

An ANDA applicant may certify against Orange Book patents using:

• Paragraph I, when no patent information is listed
• Paragraph II, when the patent has expired
• Paragraph III, when the applicant will wait until patent expiry
• Paragraph IV, when the applicant asserts that the patent is invalid, unenforceable, or not infringed

A Paragraph IV notice can trigger patent litigation within 45 days. If litigation is filed within that period, FDA approval may be subject to a statutory stay of up to 30 months, subject to statutory exceptions and court developments. [3]

For Anoro, an applicant could challenge active-ingredient, combination, formulation, or method-of-use patents depending on the Orange Book listing and the proposed labeling. A generic applicant may also seek a carve-out from a patented method of use if the remaining label supports approval.

Which companies are challenging Anoro Ellipta patents?

Publicly available litigation and FDA records should be reviewed for the current list of ANDA filers, Paragraph IV notices, and defendants. The competitive field is expected to include large generic inhaler companies and contract development organizations with inhalation-device capabilities.

The principal barriers favor companies that already have:

• Dry-powder inhaler manufacturing
• Inhalation analytical laboratories
• Device design capability
• In vitro equivalence testing
• Human factors and usability expertise
• Experience with complex generics
• Regulatory experience with device-drug combination products

Unlike a conventional oral tablet, an Anoro generic must demonstrate more than chemical sameness. Device resistance, emitted dose, aerodynamic particle-size distribution, dose uniformity, and handling performance can determine approval and litigation economics.

How strong is the Anoro Ellipta patent estate?

The patent estate is stronger when multiple independent layers remain enforceable at the same time.

Active-ingredient protection

Active-ingredient patents provide the broadest protection but are generally the earliest targets for invalidity and non-infringement analysis. Their commercial value depends on remaining term and the ability of a generic applicant to use the same active ingredients.

Combination protection

Combination claims can be important because the product uses two established pharmacologic classes in a fixed once-daily regimen. A competitor may attempt to market the ingredients separately or use a different combination, but that would not necessarily be a direct Anoro substitute.

Formulation protection

Formulation claims may cover:

• Lactose carrier selection
• Magnesium stearate concentration
• Active-to-carrier ratios
• Micronized particle properties
• Separate powder compartments
• Moisture protection
• Blend processing
• Delivered-dose performance

Formulation patents are commercially meaningful when they claim a narrow combination of composition and measurable performance. They are less effective if a competitor can obtain equivalent delivery with a materially different carrier system.

Device protection

Ellipta device patents can create a separate barrier. A competitor can pursue an Ellipta-compatible generic device, a modified Ellipta design, or a different inhaler platform. Each path creates different infringement and regulatory risks.

What generic entry risks exist for Anoro Ellipta?

The highest-risk scenario is a coordinated generic challenge covering the active ingredients, dose strengths, and device-drug combination. The likely entry pathways are:

Entry scenario	Effect on Anoro
Single generic using an equivalent Ellipta-type device	Initial price pressure and formulary substitution
Multiple generic inhalers	Faster erosion and lower net pricing
Authorized generic	Controlled price competition by the originator or licensee
Device-different generic	Slower substitution if device handling differs
Separate LAMA/LABA products	Partial substitution, particularly in restrictive formularies
Combination product with a different carrier	Potentially avoids narrow formulation claims
Hospital or payer-preferred inhaler	Volume shift without full pharmacy substitution

Device differences can delay automatic substitution even after FDA approval. Prescribers, patients, and payers may treat inhaler usability as a material product attribute. The impact depends on state substitution rules, formulary placement, contracting, and the ability of the generic sponsor to match the Ellipta device experience.

What commercial opportunities exist in Anoro Ellipta excipients?

Inhalation-grade lactose supply

The most direct opportunity is the supply of controlled-specification lactose monohydrate. Suppliers can compete through:

• Narrower particle-size distributions
• Improved lot consistency
• Low-moisture grades
• Custom fine-particle fractions
• Regulatory documentation
• Dual-source manufacturing
• Regional supply security

A supplier with validated inhalation-grade lactose can sell into branded, generic, and development programs using the same carrier platform.

Magnesium stearate surface engineering

Magnesium stearate suppliers can differentiate through particle morphology, specific surface area, purity, and controlled coating behavior. Technical service can be as important as the raw material because formulation performance depends on the mixing process and surface coverage.

Generic formulation development

A generic Anoro program may use the same excipients but must establish equivalent performance. Commercial opportunities exist for CDMOs that can provide:

• Micronization
• Carrier blending
• Low-shear or high-shear mixing
• Foil-strip filling
• Inhaler assembly
• Device testing
• Stability packaging
• Comparative aerosol characterization

Lactose-free alternatives

A lactose-free formulation could address severe milk-protein allergy labeling and create a differentiated product. Candidates could include mannitol, trehalose, glucose-based carriers, or engineered inhalation particles. The development risk is substantial because each alternative changes flow, hygroscopicity, taste, density, emitted dose, and aerodynamic behavior.

A lactose-free product would not automatically avoid all Anoro patents. It could still implicate active-ingredient, combination, dose, device, or method-of-use claims.

Device and packaging

Ellipta-type products create opportunities in moisture-barrier packaging, foil-laminate engineering, blister-strip production, and reusable or lower-material inhaler designs. Device suppliers with validated dose counters, blister opening systems, and airflow performance can support both originator lifecycle management and generic entry.

How does Anoro compare with competing COPD combinations?

Anoro competes with other long-acting bronchodilator combinations, including tiotropium-olodaterol, glycopyrrolate-formoterol, and umeclidinium-vilanterol alternatives. The competitive distinction is not limited to pharmacology.

Product attribute	Anoro Ellipta	Commercial implication
Drug class	LAMA/LABA	Targets maintenance bronchodilation
Dosing	Once daily	Supports adherence positioning
Device	Ellipta	Requires device-specific user training
Excipient model	Lactose carrier with magnesium stearate	Mature and scalable DPI platform
Main substitution risk	Other LAMA/LABA products and generics	Formulary and device competition
Biosimilar risk	None	Small-molecule generic pathway applies
Differentiation levers	Device, dose frequency, price, formulary status	Stronger than excipient identity alone

Anoro’s excipient composition is commercially conventional for a dry-powder inhaler. Its defensibility comes from the integrated product: active ingredients, powder engineering, blister packaging, inhaler mechanics, and clinical labeling.

What manufacturing and IP barriers affect Anoro competitors?

The principal manufacturing barrier is reproducible aerosol performance at scale. A competitor must control the entire chain from micronization to final device assembly.

Critical controls include:

• Active particle-size distribution
• Carrier particle-size distribution
• Blend uniformity
• Magnesium stearate distribution
• Humidity exposure
• Strip fill weight
• Foil seal integrity
• Device airflow resistance
• Delivered-dose uniformity
• Fine-particle dose
• Device-to-device variability

The principal IP barrier is claim overlap across formulation, device, and use patents. A non-infringing alternative may require a different carrier, different surface modifier, different blister architecture, or different inhaler. Those changes can create new equivalence and usability work.

What revenue exposure does Anoro face from generic entry?

Anoro revenue is exposed to price erosion, unit displacement, and loss of formulary preference after credible generic entry. The erosion pattern will depend on the number of approved competitors and whether they are substitutable at the pharmacy level.

The first generic may obtain a significant share if it matches the device and payer economics. Later entrants typically increase rebate pressure and accelerate net-price decline. An authorized generic could moderate the effect on total franchise revenue while reducing third-party generic opportunity.

Revenue exposure is also affected by competition from branded LAMA/LABA products. A payer may prefer another once-daily combination before a generic Anoro reaches the market, reducing the value of Anoro’s remaining patent term.

What licensing deals could create commercial opportunities?

Licensing opportunities may arise around:

• Inhalation-grade lactose supply
• Alternative carrier systems
• Generic Ellipta-compatible devices
• Regional commercialization rights
• Authorized-generic distribution
• CDMO manufacturing
• Foil blister and strip technology
• Device software or adherence monitoring

A licensee should evaluate whether the asset covers Anoro specifically or a broader platform applicable to other inhaled products. Platform rights are generally more valuable when they apply to multiple Ellipta products or to LAMA/LABA combinations beyond umeclidinium-vilanterol.

Key Takeaways

• Anoro Ellipta uses lactose monohydrate as the primary carrier and magnesium stearate as a powder-performance modifier.
• The commercial product is a system of active ingredients, excipients, blister strips, and Ellipta device mechanics.
• Lactose supply is widely available, but inhalation-grade particle and moisture specifications create meaningful supplier differentiation.
• Magnesium stearate is technically important because surface modification affects flow, adhesion, and aerosolization.
• Anoro is a small-molecule combination product, so generic competition proceeds through the ANDA and Paragraph IV framework, not biosimilar approval.
• Generic risk depends on active-ingredient, combination, formulation, device, and method-of-use patents.
• A lactose-free alternative could create a market distinction but would require new equivalence, stability, aerosol, and labeling work.
• The strongest commercial opportunities are in inhalation-grade excipients, generic DPI development, device manufacturing, packaging, and lifecycle-management platforms.

FAQs

Can Anoro Ellipta be reformulated without lactose?

Yes. A lactose-free carrier such as mannitol or another engineered powder carrier may be technically possible, but the reformulated product would require comprehensive aerosol-performance, stability, safety, device, and regulatory evaluation.

Does magnesium stearate improve Anoro Ellipta absorption?

Magnesium stearate primarily affects powder flow and dispersion. Its indirect effect is on the amount and aerodynamic size of powder reaching the lungs, not on systemic absorption through a conventional solubilization mechanism.

Is Anoro Ellipta a biologic drug?

No. Anoro Ellipta contains small-molecule bronchodilators and is subject to generic-drug principles rather than the biosimilar pathway.

Could a generic Anoro use a different inhaler?

Potentially. A generic applicant may develop a different device, but it must meet applicable FDA requirements for drug-device performance, labeling, usability, and equivalence. Device differences can also affect substitution and commercial uptake.

What is the main excipient risk in Anoro Ellipta?

The main risks are carrier variability, moisture sensitivity, powder segregation, magnesium stearate distribution, and the presence of milk proteins associated with lactose. These risks can affect dose delivery, labeling, and manufacturing consistency.

References

1. U.S. Food and Drug Administration. (2023). Anoro Ellipta prescribing information. GlaxoSmithKline LLC.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA guidance and applicable provisions of the Federal Food, Drug, and Cosmetic Act.